In a previous study, we evaluated the immune microenvironment of ductal carcinoma in situ (DCIS) in comparison with invasive breast cancer focusing on tumor infiltrating lymphocyte (TIL) subsets and PD-L1+ immune cells7. This evidence concerns the gene CD274 and ductal breast carcinoma in situ.